Truscreen Group Ltd. · NZX:TRU
Truscreen — ASX Small and Mid-Cap Conference (March 2024)
29 slides from Truscreen's conference presentation, Mar 27, 2024
Slide 1: TruScreen Group Ltd – A Growth Company
For personal use only TruScreen Group Ltd NZX|ASX: TRU A Growth Company 27 March 2024 Martin Dillon CEO TruScreen
Slide 2: TruScreen Group Ltd
2 TruScreen Group Ltd For personal use only ⚫ TruScreen Group Ltd - ASX and NZX TRU - is a revenue generating company with annual sales exceeding NZD $2m. ⚫ The Revenue Model: TruScreen manufactures and SELLS: o the TruScreen Real Time Cervical Cancer Screening DEVICE and o the TruScreen Disposable
Slide 3: Key achievements
Key For personal use only achievements Sales growth FY2024
Slide 4: Top achievements FY2024
4 Top achievements FY2024 For personal use only Sales and Revenue FY2024: 2024 Sales expected to be > NZD $2m Q1 – Q3 FY2024: ✓ Consumable (Single Use Sensor) 22% growth YOY ✓ Device sales 40% growth YOY ✓ China, major contributor with immense market growth opportunity
Slide 5: Device installations and SUS sales FY2019-FY2025
5 Device installations and SUS sales FY2019- FY2025 FY2019 - FY2023, actuals For personal use only FY2024 - FY025, projections* 350 we are here 250000 300 200000 250 150000 200 150 100000 100 50000 50 0 0 Mar '19 Mar '20 Mar '21 Mar '22 Mar '23 Mar '24* Mar '25* Installed Devices SUS Sales *This is
Slide 6: Top achievements FY2024
6 Top achievements FY2024 Achievements: For personal use only ✓ China: COGA Blue Book and CSCCP Guideline entries ✓ Vietnam: MOH inclusion in the National Technical List ✓ Saudi Arabia: commercial roll out and private health insurers listing
Slide 7: Top achievements FY2024
7 Top achievements FY2024 Achievements: For personal use only ✓ Zimbabwe: continues NAC screening program, TruScreen wins tenders ✓ Poland: TruScreen wins top award for implementation in the largest public hospital network for women health in Poland ✓ Mexico: TruScreen receives Cofepris approval and
Slide 8: Top achievements FY2024
8 Top achievements FY2024 Achievements: For personal use only TruScreen Group Limited recently closed a NZD $2.6m rights issue and placement confirming the markets confidence in our growth strategy. Non Executive Chairman, Tony Ho commented, “this is an outstanding result and demonstrated the confid
Slide 9: About TruScreen technology
For personal use only About TruScreen technology
Slide 10: World class technology made simple
10 WORLD CLASS technology made simple For personal use only Real-time, AI-enabled, primary cervical cancer screening device for detection of pre-cancerous and cancerous cervical tissue ► Optical and electrical measurements painlessly detect abnormalities in cervical tissue ► A Single Use Sensor (SUS
Slide 11: Trusted Clinical Performance
11 Trusted Clinical Performance For personal use only TruScreen® has been found TruScreen® has been to be as sensitive in found to be more specific Over 40,000 women in detecting CIN2+ as in detecting CIN2+ as clinical trials to date*** cytology**4 cytology**4 * CIN2: A cervical biopsy finding that
Slide 12: TruScreen's Target Markets
For personal use only TruScreen’s Target Markets
Slide 13: Cervical cancer is the fourth most common cancer in women globally
13 Cervical cancer is the fourth most common cancer in women globally For personal use only ⚫ Globally, 604 000 new cases and 342 000 deaths were recorded in 2020 ⚫ About 90% of these deaths occurred in low- and middle-income countries ⚫ The highest rates are in Africa, Central America and South-Eas
Slide 14: TruScreen's presence and markets
14 TruScreen’s presence and markets* For personal use only CE European Union: Europe CE Mark 6.7 M 13.4 M China ISO 13485 119.1 119.1 M M 119 M Registered with: Saudi 3.6 M ✓ TGA, Australia Mexico ✓ MHRA, UK 10.7 M Vietnam 8.3 M ✓ NMPA, China India ✓ SFDA, Saudi Arabia Indonesia 100.1 M 23.1 M ✓ Ros
Slide 15: China: TruScreen's largest market and growth opportunity
China: TruScreen’s largest market and growth opportunity For personal use only ● Over 300 million women of screening age, with 113 million women needing to be screened each year ● High government support for cervical cancer screening ● Made in China TruScreen status from 2021 – preferred market acce
Slide 16: China: TruScreen's largest market and growth opportunity
China: TruScreen’s largest market and growth opportunity For personal use only ● Record sales of SUS: YTD FY24 results exceeded total of FY23 ● Roll out following inclusion of TruScreen in COGA Blue Book and national CSCCP national guidelines ● Growing Consumable (SUS) usage per device
Slide 17: China, potential for SUS pull through growth
17 China, potential for SUS pull through growth For personal use only The devices in China ⚫ currently have an average pull through of 106 SUS per device per month, 24% growth in FY24 ⚫ the potential average pull-through of SUS exceeds 290 per month A B C D E F ⚫ Key accounts reach 500+ SUS pull thr
Slide 18: China, TruScreen FY2024 installations
18 China, TruScreen FY2024 installations For personal use only 72 25 December 2023, pipeline • 72 hospitals have obtained OBGYN 12 department acceptance, awaiting hospital approval • 25 hospitals have received TruScreen approval, awaiting tender completion • 12 tenders completed, awaiting hospital B
Slide 19: Vietnam: Focus market with renewed focus on public hospital rollout
Vietnam Focus market with renewed focus on public hospital rollout For personal use only The Market Opportunity ● 24m women of screening Age*, booming economy and middle class ● No centralised screening programs ● Ministry Of Health (MOH) has listed TruScreen on the National Technical List of approv
Slide 20: Vietnam: FY2024 Market Progress
Vietnam Focus market with renewed focus on public hospital rollout FY2024 Market Progress For personal use only Pipeline ● New legislation in Q1 FY 2025 to considerably shorten approval process, accelerating new installations ● 2 main hospitals received MOH approval ● 15 hospitals ready to apply to
Slide 21: FY24 Other Markets: Zimbabwe, Saudi Arabia
FY24 Other Markets For personal use only Zimbabwe ● Direct sales to Ministry of Health ● Very successful Government screening program in Masvingo province, 14 000 women screened to date, ● Two tenders won in 2023 Saudi Arabia ● Commercial rollout commenced in FY24 ● Private Health Insurance reimburs
Slide 22: FY24 Other Markets: Mexico, Poland
FY24 Other Markets Mexico For personal use only ● COFEPRIS approval granted access to public health sector Poland ● TruScreen won top award in a Mother and Child Institute challenge for healthcare companies, granting implementation in the largest public hospital network for women health in Poland
Slide 23: Outlook strategy and goals FY2024-2025
Outlook strategy For personal use only and goals FY2024-2025
Slide 24: Our Short Term Goals
24 Our Short Term Goals For personal use only Maximise Expand Grow Improve Seize the COGA Successfully expand Grow commercial Blue Book & markets in Improve the gross presence in Africa, margin by reducing CSCCP national Zimbabwe, Saudi Middle East, Central guideline window to Arabia, Vietnam and CO
Slide 25: Key take-aways
Key take-aways For personal use only ✓ Sales growth from SUS consumable usage driven by increased device installed & use ✓ China remains the biggest market with huge opportunity ✓ Global growth continues
Slide 26: www.truscreen.com
For personal use only www.truscreen.com ©
Slide 27: Contact details
For personal use only 27 Martin Dillon Guy Robertson CEO Chief Financial Officer M - +61 449 115 065 M – +61 407 983 270 E – martindillon@truscreen.com E – guyrobertson@truscreen.com TruScreen TruScreen 36 Bradfield Road, CSIRO 36 Bradfield Road, CSIRO Lindfield West NSW 2070 Lindfield West NSW 2070
Slide 28: Disclaimers
For personal use only Disclaimers truscreen This presentation has been prepared by TruScreen Group Limited (the “Company") and is dated 27 March 2024. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The informa
Slide 29: References
1. WHO, HPV and Cervical Cancer Fact sheet, 11 November 2020, https://www.who.int/news- room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer For personal use only 2. WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), 2020 3. Human papillomavirus and cancer (who.int) 4. W
TruScreen Group — ASX Small and Mid-Cap Conference (March 2024) on 6ix